Vincent Tam to Pseudomonas Infections
This is a "connection" page, showing publications Vincent Tam has written about Pseudomonas Infections.
Connection Strength
4.867
-
Clinical outcomes of cystic fibrosis patients with Pseudomonas aeruginosa bloodstream infection. J Glob Antimicrob Resist. 2022 06; 29:551-552.
Score: 0.771
-
Real life experience with ceftolozane/tazobactam therapy for Pseudomonas aeruginosa bacteremia. J Chemother. 2021 Dec; 33(8):595-597.
Score: 0.730
-
Outcomes of empiric aminoglycoside monotherapy for Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2019 Apr; 93(4):346-348.
Score: 0.622
-
Transcriptional profiles of pulmonary innate immune responses to isogenic antibiotic-susceptible and multidrug-resistant Pseudomonas aeruginosa. Microbiol Immunol. 2018 Apr; 62(4):291-294.
Score: 0.596
-
Impact of hyperglycemia on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2016 Feb; 84(2):155-8.
Score: 0.504
-
Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model. Int J Antimicrob Agents. 2013 Dec; 42(6):559-64.
Score: 0.433
-
Pseudomonas aeruginosa treatment and transmission reduction. Expert Rev Anti Infect Ther. 2013 Aug; 11(8):831-7.
Score: 0.432
-
Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2013 Mar; 57(3):1270-4.
Score: 0.414
-
The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy. Antimicrob Agents Chemother. 2024 01 10; 68(1):e0100923.
Score: 0.221
-
Ceftolozane/tazobactam activity against meropenem-non-susceptible Pseudomonas aeruginosa bloodstream infection isolates. J Glob Antimicrob Resist. 2017 12; 11:154-155.
Score: 0.145